Literature DB >> 30047148

Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study.

Brian Claggett1, Lu Tian2, Haoda Fu3, Scott D Solomon1, Lee-Jen Wei4.   

Abstract

To evaluate the totality of one treatment's benefit/risk profile relative to an alternative treatment via a longitudinal comparative clinical study, the timing and occurrence of multiple clinical events are typically collected during the patient's follow-up. These multiple observations reflect the patient's disease progression/burden over time. The standard practice is to create a composite endpoint from the multiple outcomes, the timing of the occurrence of the first clinical event, to evaluate the treatment via the standard survival analysis techniques. By ignoring all events after the composite outcome, this type of assessment may not be ideal. Various parametric or semiparametric procedures have been extensively discussed in the literature for the purposes of analyzing multiple event-time data. Many existing methods were developed based on extensive model assumptions. When the model assumptions are not plausible, the resulting inferences for the treatment effect may be misleading. In this article, we propose a simple, nonparametric inference procedure to quantify the treatment effect, which has an intuitive clinically meaningful interpretation. We use the data from a cardiovascular clinical trial for heart failure to illustrate the procedure. A simulation study is also conducted to evaluate the performance of the new proposal.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Wei-Lin-Weissfeld procedure; clinical trials; composite endpoint; counting process; multiple outcomes; nonparametric estimation; survival analysis

Mesh:

Year:  2018        PMID: 30047148      PMCID: PMC7021204          DOI: 10.1002/sim.7907

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  24 in total

1.  Nonparametric analysis of recurrent events and death.

Authors:  D Ghosh; D Y Lin
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Regression analysis of incomplete medical cost data.

Authors:  D Y Lin
Journal:  Stat Med       Date:  2003-04-15       Impact factor: 2.373

3.  Shared frailty models for recurrent events and a terminal event.

Authors:  Lei Liu; Robert A Wolfe; Xuelin Huang
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

4.  Semiparametric regression for the weighted composite endpoint of recurrent and terminal events.

Authors:  Lu Mao; D Y Lin
Journal:  Biostatistics       Date:  2015-12-14       Impact factor: 5.899

5.  Predicting the restricted mean event time with the subject's baseline covariates in survival analysis.

Authors:  Lu Tian; Lihui Zhao; L J Wei
Journal:  Biostatistics       Date:  2013-11-29       Impact factor: 5.899

6.  Joint Modeling and Estimation for Recurrent Event Processes and Failure Time Data.

Authors:  Chiung-Yu Huang; Mei-Cheng Wang
Journal:  J Am Stat Assoc       Date:  2004-12       Impact factor: 5.033

7.  Estimating medical costs from incomplete follow-up data.

Authors:  D Y Lin; E J Feuer; R Etzioni; Y Wax
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

Review 8.  Quality adjusted survival analysis.

Authors:  P P Glasziou; R J Simes; R D Gelber
Journal:  Stat Med       Date:  1990-11       Impact factor: 2.373

9.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

10.  Statistical inference methods for recurrent event processes with shape and size parameters.

Authors:  Mei-Cheng Wang; Chiung-Yu Huang
Journal:  Biometrika       Date:  2014-09-01       Impact factor: 2.445

View more
  2 in total

1.  Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies.

Authors:  Zachary R McCaw; Lu Tian; Jiawei Wei; Brian Lee Claggett; Frank Bretz; Garrett Fitzmaurice; Lee-Jen Wei
Journal:  Stat Med       Date:  2021-12-10       Impact factor: 2.373

2.  Statistical models for composite endpoints of death and non-fatal events: a review.

Authors:  Lu Mao; KyungMann Kim
Journal:  Stat Biopharm Res       Date:  2021-07-06       Impact factor: 1.586

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.